We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+48.92%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.15B
AUM Growth
+$1.69B
Cap. Flow
+$592M
Cap. Flow %
8.27%
Top 10 Hldgs %
50.83%
Holding
92
New
22
Increased
4
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$275M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$173M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$144M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$101M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$77.9M

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$134M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$109M
3
PCVX icon
Vaxcyte
PCVX
+$58.5M
4
VXRT
Vaxart
VXRT
+$51.3M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Financials 0.3%
3 Miscellaneous 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
26
Black Diamond Therapeutics
BDTX
$113M
$83M 1.16%
2,589,904
– –
SPRY icon
27
ARS Pharmaceuticals
SPRY
$423M
$80.7M 1.13%
+1,742,186
New +$58.2M
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
$77.8M 1.09%
5,290,481
-872,213
-14% -$12.6M
SLDB icon
29
Solid Biosciences
SLDB
$897M
$75.6M 1.06%
665,105
+360,361
+118% +$22.8M
KALA icon
30
KALA BIO
KALA
$9.82M
$73.7M 1.03%
4,354
– –
FPRX
31
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$72.9M 1.02%
+4,285,161
New +$53.7M
INBX
32
DELISTED
Inhibrx, Inc. Common Stock
INBX
$70.2M 0.98%
2,129,003
– –
LEGN icon
33
Legend Biotech
LEGN
$3.44B
$67.8M 0.95%
2,408,292
– –
CRIS icon
34
Curis
CRIS
$2.74M
$63.1M 0.88%
+19,269
New +$23.1M
WVE icon
35
Wave Life Sciences
WVE
$879M
$61.2M 0.86%
7,775,207
– –
CRDF icon
36
Cardiff Oncology
CRDF
$104M
$59.2M 0.83%
3,290,000
– –
DYN icon
37
Dyne Therapeutics
DYN
$3.34B
$58.9M 0.82%
2,805,045
– –
CNST
38
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$53.4M 0.75%
+1,852,746
New +$46.6M
PACB icon
39
Pacific Biosciences
PACB
$417M
$51.6M 0.72%
+1,987,997
New +$33.8M
GERN icon
40
Geron
GERN
$842M
$47.9M 0.67%
30,126,299
– –
STRO icon
41
Sutro Biopharma
STRO
$275M
$46M 0.64%
211,821
– –
CCCC icon
42
C4 Therapeutics
CCCC
$422M
$45.6M 0.64%
+1,377,569
New +$39.9M
AKUS
43
DELISTED
Akouos Inc
AKUS
$45.2M 0.63%
2,281,249
– –
RLAY icon
44
Relay Therapeutics
RLAY
$4.16B
$41.6M 0.58%
1,000,000
– –
INZY
45
DELISTED
Inozyme Pharma
INZY
$41.4M 0.58%
2,003,653
– –
ORTX
46
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$41.2M 0.58%
1,231,521
– –
ARDX icon
47
Ardelyx
ARDX
$878M
$39.9M 0.56%
6,163,086
-97,818
-2% -$581K
CERE
48
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$36.5M 0.51%
+2,200,000
New +$28.6M
ARQT icon
49
Arcutis Biotherapeutics
ARQT
$2.96B
$32.8M 0.46%
1,165,184
– –
LRMR icon
50
Larimar Therapeutics
LRMR
$406M
$32.4M 0.45%
1,515,151
– –
1
2
3 4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, RA Capital Management held 92 positions worth $7.15B, up 31% from $5.47B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management deployed $592M of net new capital in Q4 2020, opening 22 new positions and adding to 4 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,368,451 shares worth $224M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $58.5M trimmed.

  • RA Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 5,368,451 shares worth $224M.
  • RA Capital Management added most to Novavax in Q4 2020, an estimated $275M increase.
  • RA Capital Management's biggest Q4 2020 reduction was Vaxcyte, cutting an estimated $58.5M.
  • RA Capital Management fully exited Seres Therapeutics in Q4 2020, selling an estimated $134M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.15B portfolio in Q4 2020.
  • RA Capital Management opened 22 new positions and closed 10 in Q4 2020.
  • RA Capital Management's portfolio value rose 31% quarter-over-quarter to $7.15B.

Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.